· ST-PRI-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The evidence here consistently points the same way: statins lower the chance of heart attacks, strokes and related events in people at high risk who have not yet had such an event. A long-term trial in high-risk men [8] showed fewer deaths overall and fewer deaths from heart disease, and analyses from a large trial of people with raised inflammation [5][7][11] showed first cardiovascular events were cut substantially, including in women. A pooled analysis [10] found the benefit was larger in people at the highest baseline risk. The main caveat is that almost all of this rests on just two actual trials, one of which was stopped early, so the apparent breadth of evidence is narrower than the number of papers suggests. Several of the included papers were really about blood markers rather than testing the statin effect head-on. The direction of the evidence is not contradicted anywhere in this corpus.
A dedicated primary-prevention trial in high-risk men [8] reports reduced all-cause mortality (hazard ratio 0.87, 95% CI 0.80-0.94) driven mainly by a 21% fall in cardiovascular death (hazard ratio 0.79, 95% CI 0.69-0.90), with lower rates of coronary events and myocardial infarction over 20 years. JUPITER-derived primary analyses show rosuvastatin reduced first cardiovascular events by 44% overall [5], consistently across troponin and BNP strata with adjusted hazard ratios of 0.50-0.60 [7], and in women specifically (hazard ratio 0.54, 95% CI 0.37-0.80) [11]. A pooled primary-data analysis [10] found a 44% relative risk reduction in the high genetic risk subgroup versus 24% in all others, with an absolute risk reduction of 3.6% at high risk. No included primary source contradicts the claim. The contested point: The division is not over direction but over how much independent evidence actually underpins it: three included papers [5][7][11] are secondary analyses of the single JUPITER trial and one [10] leans on WOSCOPS, leaving effectively two independent trials. Compounding this, JUPITER was stopped early after a median 1.9 years of follow-up, which the panel notes tends to inflate the observed effect.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Statins, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Three of five included sources ([5], [7], [11]) are secondary analyses of the single JUPITER trial and [10] leans on WOSCOPS, so the independent-trial base is effectively two trials (WOSCOPS, JUPITER), not five independent studies.
JUPITER was stopped early (median follow-up 1.9 years per the corpus), which tends to inflate the observed effect size for the JUPITER-derived estimates.
Where it remains uncertain. The apparent weight of five included papers reduces to effectively two independent trials (WOSCOPS and JUPITER), one of them stopped early at a median 1.9 years [9], and several JUPITER papers [5][7] primarily interrogate biomarkers rather than the event endpoint directly.
Aleatory
First-event endpoints rest on relatively few events (e.g. 234 first CVD events in [6], 240 events in the primary-prevention women's meta-analysis in [11]), so chance variation around the effect size is non-trivial.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large relative reduction in first CV events in an elevated-CRP primary-prevention cohort.
“For 17,802 patients in the JUPITER trial, rosuvastatin 20 mg per day reduced the incidence of the primary endpoint by 44% (p<0.0001).”
Panel auditInternal validity: high · scope of inference: Adults without diabetes or prior CVD with LDL <3.37 mmol/L and hsCRP ≥2 mg/L.Key limitations: hsCRP-selected population · HDL-focused analysis
Statin CV-event benefit robust across risk-biomarker strata in a primary-prevention trial.
“The benefits of rosuvastatin were substantial and consistent regardless of baseline hsTnI or BNP concentrations.”
Panel auditInternal validity: high · scope of inference: Contemporary primary prevention population selected on hsCRP, stratified by cardiac biomarkers.Key limitations: hsCRP-selected population · benefit reported as consistent across subgroups rather than a single headline estimate
Dedicated high-risk primary-prevention RCT showing statin reduces CV death and all-cause mortality.
“Men allocated to pravastatin had reduced all-cause mortality (hazard ratio, 0.87; 95% confidence interval, 0.80-0.94; P=0.0007), attributable mainly to a 21% decrease in cardiovascular death (hazard ratio, 0.79; 95% confidence interval, 0.69-0.90; P=0.0004).”
Panel auditInternal validity: high · scope of inference: 45-64 year-old men with high LDL cholesterol and no prior CVD.Key limitations: men only · post-trial statin use unrecorded for final 10 years
3 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple included primary RCTs and pooled primary-data analyses consistently show statins reducing cardiovascular events in high-risk primary-prevention populations, bounded only by limited trial independence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Third independent primary-prevention statin RCT. The verdict rests on effectively two trials; an independent high-risk primary-prevention statin-vs-placebo trial would test whether the magnitude replicates. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A dedicated placebo-controlled statin RCT in a defined high-risk primary-prevention cohort run to a prespecified event-driven endpoint without early stopping.
Open question: Does the statin event benefit in high-risk primary prevention replicate in a trial independent of WOSCOPS and JUPITER? Why it is still open: Three of five included papers [5][7][11] derive from JUPITER and [10] from WOSCOPS, so the independent base is only two trials.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19